1st International Conference on Chemo and BioInformatics, ICCBIKG  2021, (320-323)

AUTHOR(S) / АУТОР(И): Jovica Branković, Vesna Milovanović, Zorica D. Petrović, Vladimir P. Petrović


Download Full Pdf   

DOI: 10.46793/ICCBI21.320B


Gallic hydrazones, as gallic acid derivatives, are known as pharmacophores of numerous multipotent agents. Among them, antiproliferative activity is one of the most important. On the other hand, thioredoxin reductase (TrxR1) is a part of the thioredoxin system, one of the most important systems responsible for maintaining the redox equilibrium inside the cell. It is overexpressed in different forms of tumors. Bearing this in mind, TrxR1 is a valid target for the development of compounds with potential antiproliferative activity. For this purpose, eight gallic acid-based hydrazones are selected and examined in silico for their potential inhibitory activity towards TrxR1.


Gallic acid, hydrazones, molecular docking, TrxR1


  • Badhani, N. Sharma, R. Kakkar, Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications, RSC Advances, 5 (2015) 27540–27557.
  • N.A. AL Zahrani, R.M. El-Shishtawy, A.M. Asiri, Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: A review, European Journal of Medicinal Chemistry, 204 (2020) 112609.
  • K.K. Sohi, N. Mittal, M.K. Hundal, K.L. Khanduja, Gallic Acid, an Antioxidant, Exhibits Antiapoptotic Potential in Normal Human Lymphocytes: A Bcl-2 Independent Mechanism, Journal of Nutritional Science and Vitaminology, 49 (2003) 221–227.
  • B.H. Kroes, A.J.J. van den Berg, H.C. Quarles van Ufford, H. van Dijk, R.P. Labadie, Anti- Inflammatory Activity of Gallic Acid, Planta Medica, 58 (1992) 499–504.
  • Inoue, R. Suzuki, N. Sakaguchi, Z. Li, T. Takeda, Y. Ogihara, B.Y. Jiang, Y. Chen, Selective Induction of Cell Death in Cancer Cells by Gallic Acid, Biological and Pharmaceutical Bulletin, 18 (1995) 1526–1530.
  • Inoue, N. Sakaguchi, K. Isuzugawa, H. Tani, Y. Ogihara, Role of Reactive Oxygen Species in Gallic Acid-Induced Apoptosis, Biological and Pharmaceutical Bulletin, 23 (2000) 1153– 1157.
  • Gichner, F. Pospíšil, J. Velemínský, V. Volkeová, J. Volke, Two types of antimutagenic effects of gallic and tannic acids towards N-nitroso-compounds-induced mutagenicity in the amesSalmonella Assay, Folia Microbiologica, 32 (1987) 55–62.
  • Gao, J. Hu, D. Hu, X. Yang, A Role of Gallic Acid in Oxidative Damage Diseases: A Comprehensive Review, Natural Product Communications, 14 (2019) 1–9.
  • G.-C. Yen, P.-D. Duh, H.-L. Tsai, Antioxidant and pro-oxidant properties of ascorbic acid and gallic acid, Food Chemistry, 79 (2002) 307–313.
  • Y.-C. Chia, R. Rajbanshi, C. Calhoun, R.H. Chiu, Anti-Neoplastic Effects of Gallic Acid, a Major Component of Toona sinensis Leaf Extract, on Oral Squamous Carcinoma Cells, Molecules, 15 (2010) 8377–8389.
  • Shabani, Z. Rabiei, H. Amini-Khoei, Exploring the multifaceted neuroprotective actions of gallic acid: a review, International Journal of Food Properties, 23 (2020) 736–752.
  • Nomura, A. Hosoda, H. Morishita, A. Murakami, K. Koshimizu, H. Ohigashi, H. Taniguchi, Synthesis of Novel Polyphenols Consisted of Ferulic and Gallic Acids, and Their Inhibitory Effects on Phorbol Ester-Induced Epstein–Barr Virus Activation and Superoxide Generation, Bioorganic & Medicinal Chemistry, 10 (2002) 1069–1075.
  • Hejchman, P. Taciak, S. Kowalski, D. Maciejewska, A. Czajkowska, J. Borowska, D. Śladowski, I. Młynarczuk-Biały, Synthesis and anticancer activity of 7-hydroxycoumarinyl gallates, Pharmacological Reports, 67 (2015) 236–244.
  • V.D. Saharan, S.S. Mahajan, Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis, Bioorganic & Medicinal Chemistry Letters, 27 (2017) 808–815.
  • M.M. da Silva, M. Comin, T.S. Duarte, M.A. Foglio, J.E. de Carvalho, M. do Carmo Vieira,
  • A.S.N. Formagio, Synthesis, Antiproliferative Activity and Molecular Properties Predictions of Galloyl Derivatives, Molecules, 20 (2015) 5360–5373.
  • Chupakhin, M. Krasavin, Thioredoxin reductase inhibitors: updated patent review (2017- present), Expert Opinion on Therapeutic Patents, 31 (2021) 745–758.
  • L.V. Papp, J. Lu, A. Holmgren, K.K. Khanna, From Selenium to Selenoproteins: Synthesis, Identity, and Their Role in Human Health, Antioxidants & Redox Signaling, 9 (2007) 775–806.
  • Scalcon, A. Bindoli, M.P. Rigobello, Significance of the mitochondrial thioredoxin reductase in cancer cells: An update on role, targets and inhibitors, Free Radical Biology & Medicine, 127 (2018) 62–79.
  • E.S.J. Arnér, Targeting the Selenoprotein Thioredoxin Reductase 1 for Anticancer Therapy, Advances in Cancer Research, 136 (2017) 139–151.
  • Zhang, B. Zhang, X. Li, X. Han, R. Liu, J. Fang, Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update, Medicinal Research Reviews, 39 (2019) 5–39.
  • Jovanović, D. Zhukovsky, A. Podolski-Renić, I. Domračeva, R. Žalubovskis, M. Senćanski,Glišić, V. Sharoyko, T. Tennikova, D. Dar’in, M. Pešić, M. Krasavin, Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy, European Journal of Medicinal Chemistry, 181 (2019) 111580.